Nigeria - 2018 - Health

NAFDAC Pharmacovigilance and Post-Marketing Surveillance (PV/PMS) Directorate Guidelines for Post Marketing Surveillance in Nigeria

Ministry of Industry, Trade and Investment, National Agency for Food and Drug Administration and Control, Nigeria

The purpose of this guideline is to strengthen NAFDAC system for effective post marketing surveillance of medicines, and regulated products including medical devices to ensure that only quality and safe medicines and other regulated products are distributed throughout the country. The implementation of This guideline will enable NAFDAC generate scientific evidence on the quality and safety of medicines and medical devices for improved health outcome.

Process Flow

Department of Pharmacovigilance& Post Marketing Surveillance

Office of the Director General NAFDAC

Office of the Permanent Secretary, Ministry of Health

Office of the Minister of State for Health

Office of the minister for health

Federal Executive Council

Contacts

Approver

Fraden Bitrus

Deputy Director i/c

National Agency for Food and Drug Administration and Control (NAFDAC)

Approver

Moji Adeyeye

Director General

National Agency for Food and Drug Administration and Control (NAFDAC)

Approver

Mahmuda Mamman

Permanent Secretary

Ministry of Health

Approver

Adeleke O. Mamora

Honourable Minister of State

Ministry of Health

Approver

Osagie Ehanire

Honourable Minister

Ministry of Health

Approver

Muhammadu Buhari

President of the Federal Republic of Nigeria

Compare Versions Please select two versions

NAFDAC Pharmacovigilance and Post-Marketing Surveillance (PV/PMS) Directorate Guidelines for Post Marketing Surveillance in Nigeria Current Version

January 2022

The purpose of this guideline is to strengthen NAFDAC system for effective post marketing surveillance of medicines, and regulated products including medical devices to ensure that only quality and safe medicines and other regulated products are distributed throughout the country. The implementation of This guideline will enable NAFDAC generate scientific evidence on the quality and safety of medicines and medical devices for improved health outcome.

Request Expert Analysis

Ask one of our policy analysts to take an in-depth look at this policy and provide you with a written summary. An additional cost may apply. Please let us know what questions you are looking to answer.

Thank you for requesting an expert analysis

A member of our team will review your request and reply back to the email address on file.